Mega Biotech & Electronics Co., Ltd. (stock code: 4415, abbreviated as Mega Biotech and formerly known as Chinlung and Chengfeng) allegedly gave false information on its periodic financial reports from 2009, in violation of the Securities and Exchange Act. To protect the rights of investors, the Securities and Futures Investors Protection Center (abbreviated as SFIPC) is now taking applications from goodwill investors who suffer losses in the above-mentioned case, and preparing to file a compensatory civil lawsuit, based on the information written in the indictment by prosecutors. Those meeting the eligibility requirements should gather all documents, fill out the forms and send them to SFIPC by Feb. 4, 2013, as shown on the postmark. For further inquiries, please check the Center’s website at http://www/sfipc.org.tw or call us at (02)2712-8899.
According to the indictment by the Kaohsiung District Prosecutors Office, Mega Biotech chairman Lee Cheng-yueh and others allegedly used an overseas paper company to make false records of trade among three parties. They made fraudulent shipment and accounting papers and included untruthful information in the firm’s periodic financial reports of 2009 and later year for violating Paragraph II, Article 20 and Article 171 of the Securities and Exchange Act. The case is now being handled at the Kaohsiung District Court.
※ Eligibility requirements:
1. Goodwill stock buyers: Those who purchased Mega Biotech shares at any time between March 4, 2010(inclusive) and Aug. 31, 2011(inclusive) and still hold those shares; or those who purchased the shares during the above-mentioned period and sold them on or after Sept. 1, 2011(inclusive), and incurred losses.
2. Stock holders: Those who purchased Mega Biotech shares at any time between Jan. 13, 2006(inclusive) and March 3, 2010(inclusive) and who still hold those shares; or those who purchased the shares during the above-mentioned period and sold them on or after Sept. 1, 2011(inclusive), and incurred losses.
Menu
Share
